Back to Peptide Library
Growth Hormone Secretagogue Blend

CJC-1295 No DAC + Ipamorelin

GHRH Analog + Selective Ghrelin-Receptor Agonist

CJC-1295 No DAC and Ipamorelin are commonly combined to stimulate growth-hormone release through complementary GHRH and ghrelin-receptor pathways. The blend is not FDA approved, has not been tested as a combination in a published randomized trial in healthy adults, and most dosing guidance comes from clinical practice and peptide communities.

Routes
SubQ
Compound type
Peptide blend
Regulatory status
Not FDA approved
Last reviewed
September 25, 2026
At a glance

CJC-1295 No DAC + Ipamorelin Quick Reference

Community Dose
Members only
Sign in to view dosing details.
Cycle
Members only
Sign in to view dosing details.
Route
SubQ Injection
The community route discussed for this blend.
Class
GH Secretagogues
GHRH-analog and ghrelin-receptor pathways.
Overview

What Is CJC-1295 No DAC + Ipamorelin?

CJC-1295 No DAC + Ipamorelin combines two growth-hormone secretagogues that act through different signaling pathways. CJC-1295 No DAC, also called Mod GRF 1-29, is a short-acting analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a selective agonist of the ghrelin or growth-hormone secretagogue receptor.

GHRH signaling encourages pituitary cells to synthesize and release growth hormone. Ipamorelin acts through a separate receptor system to trigger release of stored growth hormone. Human physiology studies support synergy between these pathway classes, but no published randomized controlled trial has established the efficacy or safety of this specific blend in healthy adults.

The no-DAC peptide is short acting. CJC-1295 with DAC has a drug-affinity modification that extends its activity; results from long-acting CJC-1295 trials cannot be transferred directly to Mod GRF 1-29.

Mechanism

CJC-1295 No DAC + Ipamorelin Mechanism of Action

GHRH-receptor signal

CJC-1295 No DAC acts as a short-acting GHRH analog, encouraging pituitary somatotroph cells to synthesize and release growth hormone.

Ghrelin-receptor signal

Ipamorelin activates the growth-hormone secretagogue receptor through a complementary pathway that promotes release of stored GH.

Pulsatile GH response

The pairing is used to amplify endogenous GH pulses and downstream IGF-1 signaling rather than directly supplying exogenous growth hormone.

Evidence boundary

Human physiology supports pathway-level synergy, but the exact no-DAC and Ipamorelin blend has not been validated in a randomized efficacy trial.

Research findings

CJC-1295 No DAC + Ipamorelin Benefits

The proposed benefits are linked to GH and downstream IGF-1 signaling. Claims for this exact combination rely heavily on physiology, individual-compound research, and community reports.

Growth Hormone & IGF-1

The intended effect is amplification of endogenous GH pulses. Human trials of long-acting CJC-1295 with DAC are not direct evidence for this short-acting blend.

Sleep Quality

Improved sleep is a common community report, but controlled studies have not shown that this blend improves sleep in healthy adults.

Training Recovery

Users often describe less soreness and steadier recovery. Controlled trials have not shown accelerated recovery from this combination.

Body Composition

GH supports lipolysis, but visible fat loss is not guaranteed and depends on nutrition, training, sleep, and baseline hormone status.

Connective Tissue & Skin

Longer-term users report joint comfort and skin changes; these remain anecdotal and do not establish structural tissue repair.

Cognition & Mood

Some users describe improved clarity or mood, but research on cognitive outcomes from the blend is sparse.

Protocol planning

CJC-1295 No DAC + Ipamorelin Dosing Protocol

Members Access Only

Sign in or create a free account to view this content.

Preparation

CJC-1295 No DAC + Ipamorelin Reconstitution

Reconstitution Example

10mg blend vial + 2mL bacteriostatic water

Result5mg/mL combined

Reconstitution steps

1
Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2
Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial. A 10mg blend vial contains 5mg of each peptide; with 2mL, the concentration is 2.5mg/mL of each.

3
Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake.

4
Storage

Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.

N=1 reports

CJC-1295 No DAC + Ipamorelin Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

  • Improved sleep quality is the most frequently reported benefit, often described within the first 1–2 weeks.
  • Longer-term users describe gradual rather than dramatic body-composition changes when diet and training are consistent.
  • Reduced post-training soreness and improved recovery frequency are reported during the first month.
  • Skin, joint, and tendon comfort changes are reported less often and generally after several months.
  • Vivid or intense dreams are frequently reported early in a cycle.

Negative & Mixed Reports

  • Some users report temporary early sleep disruption or multiple nighttime awakenings.
  • Mild water retention, facial puffiness, flushing, or lightheadedness recur in community reports.
  • Headache, fatigue, increased hunger, or injection-site welts are also described.
  • Numbness, tingling, joint swelling, persistent edema, and changes in glucose control are more concerning reports.
Stacking & synergy

CJC-1295 No DAC + Ipamorelin Stacking & Synergy

The following pairings are discussed in clinical practice or peptide communities; controlled studies of these combinations are lacking.

With TRT

TRT and GH secretagogues act through different endocrine pathways. Combined use may increase fluid retention, sleep-apnea risk, glucose effects, and monitoring needs.

With GLP-1–Based Therapy

Delayed gastric emptying and reduced caloric intake can complicate timing, nutrition, glucose control, and recovery.

With BPC-157 / TB-500

These compounds have different proposed targets and do not share the same fasting convention. No clinical studies evaluate the combination.

With MOTS-c or SS-31

Mitochondrial peptides and GH secretagogues act through different proposed pathways; concurrent use remains experimental and unstudied.

Safety notes

CJC-1295 No DAC + Ipamorelin Side Effects & Safety

Human safety data for long-acting CJC-1295 and Ipamorelin do not establish the safety of this no-DAC combination, its community doses, or long-term use in healthy adults. Unregulated injectable products also introduce sterility, impurity, and dosing risks.

FDA has identified safety concerns involving compounded CJC-1295 products, including reports of increased heart rate and systemic vasodilatory reactions.

Common User Reports

  • Injection-site redness or irritation.
  • Mild water retention or facial puffiness.
  • Flushing shortly after injection.
  • Vivid dreams or altered sleep.
  • Mild lightheadedness.

Concerning Reports

  • Headache, fatigue, or increased hunger.
  • Numbness, tingling, or carpal-tunnel-like symptoms.
  • Joint swelling or persistent edema.
  • Changes in fasting glucose or insulin sensitivity.
  • Palpitations, marked flushing, or systemic reactions.

CJC-1295 No DAC + Ipamorelin Precautions

Avoid or Discuss With a Clinician If
  • You have active cancer or an unresolved tumor.
  • You have proliferative or severe diabetic retinopathy.
  • You have uncontrolled diabetes.
  • You are pregnant or breastfeeding.
  • You have a known hypersensitivity to either peptide or product components.
Use Caution With
  • Prediabetes or type 2 diabetes.
  • A history of carpal tunnel syndrome, edema, or joint swelling.
  • Cardiovascular disease, uncontrolled hypertension, or arrhythmia.
  • Kidney or liver disease.
  • Untreated obstructive sleep apnea.
  • Concurrent insulin, diabetes medications, or glucocorticoids.
  • Exogenous HGH or IGF-1. Do not self-combine; overlapping endocrine effects make the response unpredictable.
CJC-1295 No DAC and Ipamorelin are not FDA-approved therapies for anti-aging, fat loss, athletic recovery, or general wellness.
Final verdict

Peptide Protocols Verdict on CJC-1295 No DAC + Ipamorelin

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion

We still consider the CJC-1295 No DAC + Ipamorelin combination the gold standard daily growth hormone stack. These two peptides work best as a team — running either one separately significantly reduces the effectiveness and you’re simply not maximizing the potential. Together they deliver reliable GH pulses, enhanced recovery, better sleep, and solid muscle preservation with a relatively favorable side effect profile.

The community keeps returning to this pairing because it simply works well across recomp, healing, and longevity goals. That said, it does tend to leave welts at injection sites for many users, so proper rotation and technique matter. More is not better here — stick to standard protocol dosing for optimal results without unnecessary sides.

Clean, consistent, and effective when used correctly. A foundational stack that remains hard to beat for everyday optimization.